Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue
Viemed Healthcare reported Q3 2026 record revenue of $80M. CEO Casey Boyd discussed state rollout timelines, expecting gradual growth. CFO Trey Fitzgerald addressed sequential growth gaps, seasonal trends, and financial KPIs, targeting EBITDA above 20%. Accounts receivable delays impacted cash flow but are expected to resolve in Q4. Boyd also updated on sales force training, M&A pipeline, and patient education progress.
How this was made

The 30-second read
Why it matters
Management's comments on margin targets and AR resolution suggest operational improvements, but cash conversion remains a risk.
Market read
Earnings call provides fresh guidance for a micro‑cap health‑tech stock, offering limited but actionable insight for traders.
What to watch
Potential regulatory changes in maternal health reimbursement and competitive pressure from larger health‑tech firms.
Background
Viemed Healthcare provides home‑based respiratory and maternal health services; the Q3 2026 call covered operational metrics and future growth plans.
Ticker impact
Q3 2026 earnings call disclosed record revenue, free cash flow of $26‑27M, AR $35M and guidance on growth and margins.
potential modest upside as investors price in continued revenue growth and margin expansion
Guidance is positive but not extraordinary; market may react positively but limited by company size.
Market effects
Signals continued demand in home‑based respiratory and maternal health services, modestly supportive for the broader health‑tech sector.
Limited to U.S. healthcare investors; no broader regional effect.
Low global relevance; primarily a micro‑cap US health‑tech story.
Counterpoint
Guidance may be overly optimistic given rising AR and cash conversion delays; stock could face pressure if cash flow does not improve.
Key entities
- ExecutiveCasey Boyd
CEO of Viemed Healthcare
- ExecutiveTrey Fitzgerald
CFO of Viemed Healthcare



